Wells Fargo & Company Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective dropped by analysts at Wells Fargo & Company from $180.00 to $175.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 40.99% from the stock’s previous close.

Several other research firms have also recently issued reports on NBIX. Citigroup increased their price objective on shares of Neurocrine Biosciences from $203.00 to $204.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Thursday, January 22nd. Canaccord Genuity Group lifted their price target on Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Wedbush upped their price objective on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Zacks Research cut Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. Sixteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.42.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $124.12 on Friday. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $160.18. The stock’s fifty day moving average is $140.14 and its 200-day moving average is $140.44. The firm has a market capitalization of $12.46 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 0.58 and a beta of 0.31.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.69 EPS. Analysts forecast that Neurocrine Biosciences will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Leslie V. Norwalk sold 1,190 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director directly owned 6,239 shares of the company’s stock, valued at $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 61,966 shares of company stock valued at $8,625,166. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Several large investors have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $25,000. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares during the period. Eastern Bank purchased a new position in Neurocrine Biosciences during the 3rd quarter valued at about $27,000. DJE Kapital AG acquired a new position in shares of Neurocrine Biosciences in the 4th quarter valued at about $28,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Multiple analysts reiterated Buy/Outperform ratings and raised some price targets (Citigroup to $204, Bank of America reiterated Buy with a $190 target, Needham nudged to $185), signaling continued confidence in Ingrezza durability and pipeline upside. Analyst moves (Benzinga / TipRanks)
• Positive Sentiment: Q4 revenue grew strongly (~28% YoY to ~$805.5M) and company commentary highlighted Ingrezza sales growth and emerging uptake of pipeline assets — supports longer-term revenue trajectory. Earnings highlights (Yahoo)
• Neutral Sentiment: Deeper analysis pieces discuss growth beyond Ingrezza and portfolio opportunities that could drive medium-term upside but caution that 2026 may be less eventful. Useful for investors assessing longer-horizon thesis. Seeking Alpha: Growth Beyond Ingrezza
• Neutral Sentiment: Full Q4 earnings call transcripts and analyst note compilations are available for investors wanting primary commentary on guidance, expense cadence, and pipeline timelines. Review for detail before trading on headlines. Earnings transcripts & summaries
• Negative Sentiment: EPS missed expectations (Q4 EPS ~$1.88 vs. several consensus figures higher), and management issued cautious 2026 guidance — the combination sparked downside pressure and short-term uncertainty. Zacks: Q4 EPS lag
• Negative Sentiment: Some firms trimmed price targets or downgraded to Market Perform (BMO to $140; RBC and Wells Fargo trimmed targets though keeping Outperform/Overweight designations), reflecting more cautious near-term outlooks. Price target changes (Benzinga)
• Negative Sentiment: Market commentary highlights the stock’s sharp pullback after guidance and the EPS miss — articles explaining recent 8%+ decline underscore the sentiment risk if sales or cost pressures persist. AAII: Why NBIX is down

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.